Washington, DC (UroToday.com) During the bladder cancer session at the Society of Urologic Oncology Meeting on Thursday, December 5 th, Dr. Colin Dinney presented the results of a phase III clinical ...

Bladder cancer is a highly recurrent disease with few treatment options available to patients,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “This program reflects our ...

The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals ...

This summary includes information from the ARCHES and ENZAMET follow-up studies. Both studies looked at enzalutamide treatment for people with metastatic hormone-sensitive prostate cancer (known as ...

Aims: Renal tissue is a dynamic biophysical microenvironment, regulating healthy function and influencing tumor development. Matrix remodelling is an iterative process and aberrant tissue repair is ...

Despite nearly 100% 5-year survival for localised prostate cancer, the survival rate for metastatic prostate cancer significantly declines to 32%. Thus, it is crucial to identify molecular indicators ...

Purpose: To classify older patients with bladder cancer (BC) based on quality-of-life (QoL) measures and explore the clusters transitions over a 2-year period and patient characteristics, BC stages, ...

There is now a plethora of mechanistic and clinical evidence that the adrenal-permissive HSD3B1 allele allows for prostate cancer to increase the synthesis of potent non-gonadal androgens. Further, ...

United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence ...

Background: The therapeutic advancements based on immune-oncology (IO) combinations have revolutionized renal cell carcinoma (RCC) management. However, patients who have progressive disease as best ...

Radical Cystectomy is indicated in muscle-invasive bladder cancer and select cases of nonmuscle invasive bladder cancer. Women often undergo additional reproductive organ removal, greatly impacting ...